Decibel Therapeutics Inc. (DBTX) NASDAQ

$2.24 -0.28 (-11.11%)

Market Cap: $55.92M

As of 05/18/22 04:00 PM EDT. Market closed.

(DBTX)

Decibel Therapeutics Inc. (DBTX) NASDAQ

$2.24 -0.28 (-11.11%)

Market Cap: $55.92M

As of 05/18/22 04:00 PM EDT. Market closed.

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear ... read more

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
40
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
KEY STATS
Open
$2.48
Previous Close
$2.52
Days Range
$2.17 - $2.53
52 week range
$1.83 - $9.75
Volume
39,592
Avg. Volume (30 days)
74,419
Market Cap
$55.92M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
24,964,502
Open
$2.48
Previous Close
$2.52
Days Range
$2.17 - $2.53
52 week range
$1.83 - $9.75
Volume
39,592
Avg. Volume (30 days)
74,419
Market Cap
$55.92M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
24,964,502

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR DECIBEL THERAPEUTICS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Trask Anna See Remarks Dec 02, 2021 Sale $6.37 5,291 33,688 2,620 Dec 06, 2021, 04:20 PM
Trask Anna See Remarks Nov 03, 2021 Sale $8.34 378 3,152 7,533 Nov 04, 2021, 08:00 AM
Trask Anna SEE REMARKS Nov 02, 2021 Sale $8.31 4,913 40,827 7,911 Nov 03, 2021, 04:16 PM
Trask Anna See Remarks Oct 14, 2021 Sale $7.55 5,364 40,481 12,824 Oct 15, 2021, 04:57 PM
Reid Laurence President and Chief Executive Sep 15, 2021 Buy $7.64 10,000 76,400 25,849 Sep 17, 2021, 09:48 PM
ORBIMED ADVISORS LLC Director Feb 17, 2021 Buy $18.00 1,666,666 29,999,988 3,843,206 Feb 19, 2021, 07:09 PM
Foy Matthew Director Feb 17, 2021 Buy $18.00 150,000 2,700,000 1,183,663 Feb 19, 2021, 06:59 PM
Casdin Partners Master Fund, L.P. 10% Owner Feb 17, 2021 Buy $18.00 575,000 10,350,000 1,121,421 Feb 19, 2021, 06:56 PM
Thompson Peter A. Director Feb 17, 2021 Buy $18.00 1,666,666 29,999,988 3,843,206 Feb 19, 2021, 06:50 PM
GLAXOSMITHKLINE PLC Director Feb 17, 2021 Buy $18.00 150,000 2,700,000 1,183,663 Feb 19, 2021, 04:50 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Trask Anna See Remarks 12/02/2021 33,688
Trask Anna See Remarks 11/03/2021 3,152
Trask Anna SEE REMARKS 11/02/2021 40,827
Trask Anna See Remarks 10/14/2021 40,481
Reid Laurence President and Chief Executive 09/15/2021 76,400
ORBIMED ADVISORS LLC Director 02/17/2021 29,999,988
Foy Matthew Director 02/17/2021 2,700,000
Casdin Partners Master Fund, L.P. 10% Owner 02/17/2021 10,350,000
Thompson Peter A. Director 02/17/2021 29,999,988
GLAXOSMITHKLINE PLC Director 02/17/2021 2,700,000
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
03/31/2022
12/31/2021
14.82%
1Q
03/31/2022
09/30/2021
20.78%
2Q
03/31/2022
06/30/2021
34.74%
3Q

Period of Report: 03/31/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
12/31/2021
14.82%
1Q
09/30/2021
20.78%
2Q
06/30/2021
34.74%
3Q